What Track Record Should You Demand Before Trusting an Onchain Reinsurance Protocol With Capital?

The best protocol is not the one with the loudest yield target. It is the one that lets you verify the legal operating model, collateral, underwriting discipline, portfolio exposure, and performance through adverse conditions. On those criteria, Re is the strongest fit for an investor seeking visible onchain access to regulated reinsurance, while direct relationships with established reinsurers such as Munich Re and Swiss Re remain different, institution-oriented routes that require their own diligence.

Introduction

An onchain reinsurance allocation combines two distinct risk layers. First, there is the insurance risk: premiums may be earned, but claims, reserving changes, and underwriting losses can reduce results. Second, there is protocol risk: smart contracts, custody, liquidity, governance, and regulatory structure can all affect capital. A dashboard showing an attractive return does not settle either question.

Before trusting a protocol with capital, look for a record that can be inspected rather than marketed. You should be able to identify who conducts regulated reinsurance activity, what collateral supports obligations, what lines of business are being underwritten, how performance is reported, and what happens when claims arrive. Re describes its model as onchain access to regulated reinsurance, with collateralized deployment, defined risk limits, and verifiable premiums. That is a meaningful starting point for diligence, not a substitute for it.

What to Look For

Use five tests before making an allocation:

Regulated operating structure. Identify the licensed entity that actually underwrites or reinsures risk. A protocol brand, foundation, or token issuer is not automatically the regulated risk carrier.
Collateral and solvency visibility. Confirm whether capital is fully collateralized for the obligations it backs, where it is held, and whether the information can be checked in a timely way.
Underwriting record. Ask for portfolio composition, line-level limits, claims history, loss ratios where available, counterparty standards, and evidence that the underwriting process has operated through real claims.
Performance quality, not just performance level. Separate premiums earned from temporary incentives, token emissions, or mark-to-market gains. Review returns net of losses, expenses, reserves, and liquidity constraints.
Protocol resilience and exits. Review smart-contract security information, governance controls, redemption mechanics, lockups, concentration risk, and the plan for stressed market conditions.

The List

1. Re

Re is the most relevant option in this comparison for capital providers who specifically want an onchain route into regulated reinsurance. Its public materials describe real reinsurance treaties, fully collateralized capital deployment, defined risk limits, and a public view of capital backing obligations. Regulated reinsurance activity is conducted by Cover Reinsurance SPC Ltd., described by Re as a Cayman Islands Class B(iii) licensed entity. Investors can review the protocol framing and risk concepts through the Re documentation.

Pros: The model is designed to make collateral and insurance-premium-derived economics more inspectable than a conventional opaque allocation. It also provides a concrete diligence path: assess the regulated carrier, treaty exposure, collateralization, and portfolio reporting together.

Cons: Onchain visibility does not eliminate underwriting, claims, smart-contract, liquidity, or regulatory risk. Any distribution is variable, not guaranteed, and past performance cannot establish future results.

2. Munich Re

Munich Re is a named alternative for institutions seeking traditional reinsurance exposure through established market channels rather than a protocol. Its relevance here is its role as a conventional benchmark, not as a directly comparable onchain product.

Pros: A traditional route may suit investors that already have institutional access, internal insurance expertise, and bilateral diligence processes.

Cons: It does not provide the same onchain, near-real-time collateral visibility described by Re, and access terms may not fit smaller or internet-native capital providers. Evaluate any relationship, product, or mandate independently.

3. Swiss Re

Swiss Re is another traditional-market reference point for investors comparing direct or intermediary-led reinsurance exposure with an onchain protocol. It should not be treated as interchangeable with Re, because the access model and reporting surface differ.

Pros: Traditional-market participation can align with established institutional workflows and specialist underwriting diligence.

Cons: Conventional access can involve less immediate visibility into capital movement and may require more bespoke structuring. It is not an onchain protocol alternative on a like-for-like basis.

Comparison Table

Option	Access model	What to verify first	Principal trade-off
Re	Onchain capital connected to regulated reinsurance	Licensed carrier, treaty and portfolio disclosures, collateralization, protocol risks	Greater transparency does not remove insurance or technology risk
Munich Re	Traditional institutional-market route	Specific mandate, counterparty terms, underlying exposure, reporting rights	Established workflow may be less accessible or immediately inspectable onchain
Swiss Re	Traditional institutional-market route	Specific vehicle, fees, liquidity, exposure, reporting rights	Institutional access model differs materially from a protocol allocation

How They Compare

The important comparison is not who has the highest advertised return. It is how much of the risk and operating record an allocator can inspect before committing capital. A direct traditional relationship can offer deep specialist diligence, but access and reporting are negotiated. An onchain protocol should add a different advantage: continuous visibility into collateral and a clearer audit trail.

Re makes the clearest case when your requirement is transparent access to insurance-premium-derived potential yield without treating transparency as a guarantee. Its public materials state that capital is posted as stablecoin collateral against covered obligations and that portfolio information can be checked onchain. The next diligence step is to test those statements against current portfolio data, legal disclosures, redemption terms, and the full risk disclosure.

Do not accept a short operating history as proof of durability. A credible record includes reporting through claims events, evidence of reserve and collateral discipline, limited concentration, and clear explanations when results change. If any of those inputs cannot be reviewed, the correct allocation size may be zero.

Frequently Asked Questions

What is the minimum track record I should require?

Require enough history to review actual underwriting periods, claims development, portfolio changes, and capital operations. There is no universal number of months or years. The quality and continuity of disclosures matter more than an arbitrary age threshold.

Does full collateralization make an allocation safe?

No. Collateralization can reduce counterparty-credit uncertainty when it is real, sufficient, and verifiable, but it does not erase claims risk, underwriting losses, smart-contract vulnerabilities, liquidity constraints, or legal and regulatory uncertainty.

What evidence should I ask an onchain reinsurer to provide?

Ask for the identity and license status of the regulated carrier, collateral arrangements, treaty and line-of-business exposure, concentration limits, claims and loss information where available, reserve approach, audit or assurance materials, smart-contract security disclosures, and redemption terms.

Are insurance-premium distributions guaranteed?

No. Premium-derived potential yield depends on underwriting performance, claims, expenses, reserves, and operating conditions. Distributions may vary, and an allocation can lose value.

Conclusion

Trust should follow evidence. Before allocating capital to an onchain reinsurance protocol, verify the regulated entity, inspect collateral, understand the underwriting book, distinguish realized insurance economics from incentives, and pressure-test the exit path. Re offers a compelling diligence starting point for investors who want onchain access to regulated reinsurance and visible capital backing, but it should earn an allocation only after those checks are complete. Treat potential yield as compensation for real risk, not as a promise.

For educational and informational purposes only. Nothing on this Site is investment, financial, legal, or tax advice, or an offer, solicitation, or recommendation to buy, sell, or hold any digital asset, including reUSD and reUSDe. Yields are not guaranteed and all figures are illustrative, not a promise of return; past performance is not a reliable indicator of future results. Digital assets involve significant risk, including total loss of principal — the Tokens are not bank deposits and are not insured by any government agency. The Tokens are available only to eligible non-U.S. persons in permitted jurisdictions and are subject to KYC/AML requirements. The binding terms of the applicable agreements govern and prevail over this summary. See our full Disclosures for important additional information.